Table 1 Characteristics of the studies included (1757 patients)
Study | Year | Country | Patient setting | Mean age (years) | Patients (n) | Patients (type) | Measuring instrument | Cut-off (pg/ml) | Study design | Prevalence (%) | Sensitivity (%) | Specificity (%) | Reference standard |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo et al. | 2012 | Japan | ED&ICU | NA | 185 | All type | PATHFAST,(Mitsubishi Chemical Medience Corporation, Japan) | 600 | PR&CR | 62.16 | 87.80 | 81.40 | ACCP/SCCM |
Liu et al. | 2013 | China | ED | 71.5 | 859 | All type | PATHFAST,(Mitsubishi Chemical Medience Corporation, Japan) | 317 | PR&CR | 79.16 | 70.80 | 85.80 | ACCP/SCCM |
Ulla et al. | 2013 | Italy | ED | 64.4 | 189 | All type | PATHFAST,(Mitsubishi Chemical Europe GmbH, Dusseldorf, Germany) | 600 | PR&CR | 56.08 | 78.95 | 61.90 | ACCP/SCCM |
Behnes et al. | 2014 | Germany | ICU | 67.9 | 96 | All type | PATHFAST,(PROGEN Biotechnik GmbH, Germany; Mitsubishi Chemical Medience Corporation, Japan) | 530 | PR | 84.38 | 90.00 | 60.00 | ACCP/SCCM |
Ishikura et al. | 2014 | Japan | ED | 67.2 | 62 | All type | PATHFAST,(Mitsubishi Chemical Medience Corporation, Japan) | 647 | PR&CR | 69.35 | 93.00 | 76.30 | ACCP/SCCM |
Kweon et al. | 2014 | Korea | ED | 64.01 | 93 | All type(without burn patients) | PATHFAST,(Mitsubishi Chemical Medience Corporation, Japan) | 430 | PR&CR | 78.49 | 87.70 | 82.20 | ACCP/SCCM |
Romualdo et al. | 2014 | Spain | ED | 67.7 | 226 | All type | PATHFAST,(Mitsubishi Chemical Europe GmbH, Dusseldorf, Germany) | 729 | PR&CR | 16.37 | 81.10 | 63.00 | ACCP/SCCM |
Godnic et al. | 2015 | Slovenia | ICU | NA | 47 | All type | PATHFAST,(Mitsubishi Chemical Europe GmbH, Dusseldorf, Germany) | 500 | PR | 85.11 | 84.60 | 62.50 | ACCP/SCCM |